治疗转移性结直肠癌的Ziv-阿柏西普的临床研究进展

Progression of Ziv-aflibercept on metastatic colorectal cancer

针对特异性分子靶点的靶向药物治疗已成为转移性结直肠癌(m CRC)治疗的新方向。2012年Ziv-阿柏西普被美国食品和药物管理局批准用于m CRC患者,Ziv-阿柏西普是一种作用于血管生成信号通路的重组融合蛋白,通过与血管内皮生长因子(VEGF)受体结合,从而阻断肿瘤的生长和转移。一项Ⅲ期临床研究结果显示Ziv-阿柏西普能显著延长m CRC患者的生存期。本文结合国内外最新研究报道,对Ziv-阿柏西普治疗m CRC的研究进展作一综述。

Targeted drug therapy for specific molecular targets has become a new direction of treatment for metastatic colorectal cancer （mCRC）. Ziv-Aflibercept was approved by the U.S. Food and Drug Administration for use in the patients with mCRC in 2012. Ziv- Aflibercept is a novel recombinant fusion protein which can inhibit growth and metastasis of tumor by blocking vascular endothelial growth factor （VEGF） receptors. A phase Ⅲclinical trial showed the benefit of Ziv-aflibercept on the overall survival of mCRC patients. In this paper, the progression of Ziv-aflibercept on mCRC are summarized.